75 citations
,
November 1996 in “Fertility and Sterility” Finasteride effectively reduces hair growth in women with idiopathic hirsutism, but requires careful contraception during treatment.
14 citations
,
February 2011 in “Drug Metabolism and Disposition” Ketoconazole increases finasteride's effectiveness and lifespan in the body.
10 citations
,
October 2010 in “International Journal of Andrology” Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
12 citations
,
October 2012 in “International Braz J Urol” Finasteride effectively and safely treats recurrent priapism in children and adolescents with sickle cell disease.
35 citations
,
February 1994 in “Fundamental and applied toxicology” High doses of finasteride cause cell growth and tumors in mice.
15 citations
,
March 2007 in “Hormones and Behavior” Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.
14 citations
,
April 2002 in “Brain Research Protocols” Quickly get finasteride from tablets using easy methods.
10 citations
,
May 2010 in “Analytica Chimica Acta” New tests detect finasteride and dutasteride in urine quickly and easily.
8 citations
,
January 1991 in “European Urology” Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.
60 citations
,
December 1998 in “Clinical Pharmacology & Therapeutics” Both drugs lower DHT levels, with GI198745 being more effective.
1 citations
,
July 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
July 2000 in “Hair transplant forum international”
50 citations
,
May 2000 in “Fertility and Sterility” Flutamide reduces hair growth better but has more side effects.
April 2006 in “Journal of Korean Pharmaceutical Sciences” May 2007 in “Inpharma Weekly”
June 2023 in “Journal of Cosmetic Dermatology” Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
April 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
February 2026 in “Archiv Euromedica” Finasteride effectively treats male hair loss, with oral and topical forms improving hair growth, but oral use may have side effects.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
June 2025 in “Journal of Cosmetic Dermatology” Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
September 2025 in “JAAD reviews.” Finasteride and dutasteride can improve hair loss in women, but more research is needed.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
September 2021 in “Clinical research in dermatology” 5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.